Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications

Lee, Mike S

ISBN 10: 0470401966 / ISBN 13: 9780470401965

Published by John Wiley & Sons Inc, 2011

About this Item

This book examines the background, industrial context, process, analytical methodology, and technology of metabolite identification. It emphasizes the applications of metabolite identification in drug research. While primarily a textbook, the book also functions as a comprehensive reference to those in the industry. Editor(s): Lee, Mike S.; Zhu, Mingshe. Series: Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods. Num Pages: 800 pages, Illustrations. BIC Classification: MMG; PN. Category: (P) Professional & Vocational. Dimension: 242 x 161 x 49. Weight in Grams: 1292. . 2011. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.

Seller Inventory # V9780470401965

Bibliographic Details

• Title: Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications
• Publisher: John Wiley & Sons Inc
• Publication Date: 2011
• Language: English
• ISBN 10: 0470401966
• ISBN 13: 9780470401965
• Binding: Hardcover
• Condition: New

About this title

Synopsis

This book examines the background, industrial context, process, analytical methodology, and technology of metabolite identification. It emphasizes the applications of metabolite identification in drug research. While primarily a textbook, the book also functions as a comprehensive reference to those in the industry. The authors have worked closely together and combine complementary backgrounds to bring technical and cultural awareness to this very important endeavor while serving to address needs within academia and industry It also contains a variety of problem sets following specific sections in the text.

About the Author

MIKE S. LEE, PhD, is President of Milestone Development Services. His recent work has involved the development of automated orthogonal control systems for electrospray ionization. Formerly, Dr. Lee was director of analytical research and development at Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute where he led interdisciplinary teams that contributed to the Food and Drug Administration's approval of Buspar® and Serzone®, and the accelerated development and approval of Taxol®. In addition, he has authored over forty scientific papers and issued patents.

MINGSHE ZHU, PhD, is a drug metabolism researcher at Bristol-Myers Squibb, where he leads a team that investigates biotransformation in new drug discovery and preclinical drug metabolism and pharmacokinetics in development. His teams have provided key metabolism and disposition information for regulatory approval of Abilify® and NDA submission of Dapagliflozin. Dr. Zhu's research interests include LC/MS technology, optimization of ADME properties, metabolic activation, and regulatory drug metabolism. He has been frequently invited to speak and teach short courses at conferences/workshops and has coauthored over sixty research articles and one book.